恩他卡朋添加治疗有剂末现象帕金森病的初步研究

Initial trial of entacapone adding on Parkinson’s patients with end-of-dose phenomenon

目的探讨恩他卡朋联合左旋多巴治疗有剂末现象的帕金森病患者(PD)的疗效及安全性。方法分别对40例服用左旋多巴伴有剂末现象的PD患者联合应用恩他卡朋自身对照研究,在试验前和添加恩他卡朋治疗后第1周、第4周、第8周、第12周分别进行"统一帕金森病评定量表"(UPDRS)评分,比较试验前和添加恩他卡朋治疗后左旋多巴每日服用总量,并对不良反应统计分析。结果加用恩他卡朋治疗后,第1周、第4周、第8周、第12周UPDRS评分均有下降,随着治疗时间延长,UPDRS评分下降明显(P<0.01);在添加治疗后第4周、第8周、第12周,左旋多巴每日服用总量下降与试验前比较有统计学意义(P<0.05),且没有发现严重不良事件(P>0.05)。结论恩他卡朋添加治疗有剂末现象的PD患者有效、安全。

Objective To investigate the efficacy and safety of entacapone in combination with levodopa in treatment of Parkinson＇s patients with end-of-dose phenomenon. Methods Self- control studies of 40 end-of- dose phenomenon Parkinson＇s patients were treated with entacapone and levodopa. Unified Parkinson＇s Disease Rating Scale （UPDRS） scores and daily levodopa dosage were assessed before experiment and in the first week, forth week, eighth week and twelfth week. And adverse effects were analyzed. Results UPDRS scores descended in the first week, forth week, eighth week and twelfth week after using entacapone, and the scores descended obviously with time of therapy extended （P〈0.01）. Daily levedopa dosages lowered significantly compared with pro-experiment and the forth week, eighth week and twelfth week （P〈0.05）.No severe harmful events appeared （P〉0.05）. Conclusion Entacapone adding for the parkinson＇s patients with end-of-dose phenomenon is effective and safe.